Bleeding characteristics of patients with congenital hemophilia and inhibitors: Data from a postmarketing study of recombinant activated factor VII (SMART-7)

被引：0
|
作者：
Demartis, Francesco [1 ]
Benson, Gary [2 ]
Batorova, Angelika [3 ]
Cepo, Katarina [4 ]
Zak, Marek [4 ]
Chambost, Herve [5 ]
机构：
[1] Azienda Osped Univ Careggi, Haemophilia Ctr, Florence, Italy
[2] Belfast City Hosp, Northern Ireland Haemophilia Ctr, Belfast, Antrim, North Ireland
[3] Comenius Univ, Fac Med, Univ Hosp, Bratislava, Slovakia
[4] Novo Nordisk AS, Soborg, Denmark
[5] Hop Enfants La Timone, Marseille Univ Hosp, Pediat Hematol Unit, Marseille, France
来源：
HAEMOPHILIA | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [1] Bleeding Characteristics Of Patients With Congenital Haemophilia And Inhibitors: Data From A Postmarketing Study Of Recombinant Activated Factor VII (SMART-7)
    Kavakli, K.
    Demartis, F.
    Benson, G.
    Cepo, K.
    Chambost, H.
    Batorova, A.
    Zak, M.
    HAEMOPHILIA, 2017, 23 : 91 - 91
  • [2] Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency
    Rajpurkar, Madhvi
    Cooper, David L.
    JOURNAL OF BLOOD MEDICINE, 2018, 9 : 227 - 239
  • [3] Prophylaxis in Congenital Hemophilia with Inhibitors: The Role of Recombinant Activated Factor VII
    Franchini, Massimo
    Manzato, Franco
    Salvagno, Gian Luca
    Montagnana, Martina
    Zaffanello, Marco
    Lippi, Giuseppe
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2009, 35 (08): : 814 - 819
  • [4] Safety of room temperature stable recombinant activated factor VII (VII25) in patients with haemophilia A or B with inhibitors: results from the prospective, non-interventional smart-7 study
    Kavakli, K.
    Chambost, H.
    Demartis, F.
    Sommer, L.
    Zak, M.
    Benson, G.
    HAEMOPHILIA, 2016, 22 : 52 - 52
  • [5] Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors
    Stephens, Jennifer M.
    Joshi, Ashish V.
    Sumner, Michael
    Botteman, Marc F.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (08) : 1127 - 1136
  • [6] The SMART-7 Study: A Prospective, Post-Authorisation Non-Interventional Study on Room Temperature Stable Recombinant Activated Factor VII (VII25) in Patients with Haemophilia A or B with Inhibitors
    Benson, G.
    El Fegoun, S. Benchikh
    Chambost, H.
    Demartis, F.
    Zak, M.
    Kavakli, K.
    HAEMOPHILIA, 2016, 22 : 54 - 55
  • [7] Benefit of Early Treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in Patients with Hemophilia a or B with Inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-Interventional SMART-7™ Study
    Benson, Gary
    Chambost, Herve
    Demartis, Francesco
    El Fegoun, Soraya Benchikh
    Cepo, Katarina
    Sommer, Lene
    Kavakli, Kaan
    BLOOD, 2016, 128 (22)
  • [8] Health economic review of recombinant activated factor VII (Novoseven®) for treatment of bleeding episodes in hemophilia patients with inhibitors.
    Stephens, Jennifer M.
    Botteman, Marc F.
    Joshi, Ashish V.
    Sumner, Michael
    BLOOD, 2006, 108 (11) : 482B - 482B
  • [9] Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors
    Chuansumrit, Ampaiwan
    Angchaisuksiri, Pantep
    Sirachainan, Nongnuch
    JOURNAL OF BLOOD MEDICINE, 2010, 1 : 37 - 48
  • [10] Single-dose recombinant activated factor VII therapy in hemophilia patients with inhibitors
    Kenet, Gili
    Martinowitz, Uri
    SEMINARS IN HEMATOLOGY, 2008, 45 (02) : S38 - S41
12345